THE EFFECT OF ROSIGLITAZONE ON OXIDATIVE STRESS AND INSULIN RESISTANCE IN OVERWEIGHT INDIVIDUALS

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12606000313538

Enrollment

Registered

2006-07-20

Start date

2003-01-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study is to determine whether the drug rosiglitazone, commonly used for people with diabetes, when used in people who are overweight reduces the levels of markers of oxidative stress and improves the action of insulin. If this was the case then this medication could potentially be considered for trials aimed at diabetes prevention. This study will specifically look at the role of this drug in people with a body mass index (weight in relation to a persons height) of >27kg/m2 (overweight). Participants will be divided in to 2 groups, one will receive the active drug and the other a placebo. At the end of the study a comparison will be made of the effectiveness of the drug compared to the placebo.

Interventions

Rosiglitazone 4mg orally per day for 6 months.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

30 Years to 65 Years

Healthy volunteers

Inclusion criteria

Healthy individuals with BMI > 27 kg/m2.

Exclusion criteria

Type 2 diabetes or known cardiovascular disease. Lipid lowering therapy, anti-inflammatory drugs, steroids. Recent surgery. Smoking.

Outcome results